Genzyme metabolic news
Genzyme said shipments of newly produced Fabrazyme agalsidase beta will be delayed to mid-December and the volume of finished product initially will be lower than expected. The company had hoped to begin shipments as early as November. From Oct. 1 through year end, Genzyme said it will ship enough of its remaining Fabrazyme to meet about 30% of global patient demand. The company said the delay in Fabrazyme shipments is due in part to a late restart of the bioreactors at its Allston, Mass. plant and a lower-than-expected product output. The company also lowered its revenue guidance for the Fabry's disease treatment to $450 million from $510-$520 million. In June, the biotech temporarily closed the Allston, Mass. manufacturing facility after a virus was found in a bioreactor (see BioCentury, June 22 & August 17). ...